ECSP14013160A - Procedimiento para la fabricación de una composición farmacéutica en forma de tabletas de liberación prolongada conteniendo pirfenidona y su aplicación en la regresión de la insuficiencia renal crónica, contractura capsular mamaria y fibrosis hepatica hu - Google Patents

Procedimiento para la fabricación de una composición farmacéutica en forma de tabletas de liberación prolongada conteniendo pirfenidona y su aplicación en la regresión de la insuficiencia renal crónica, contractura capsular mamaria y fibrosis hepatica hu

Info

Publication number
ECSP14013160A
ECSP14013160A ECSP14013160A ECSP14013160A EC SP14013160 A ECSP14013160 A EC SP14013160A EC SP14013160 A ECSP14013160 A EC SP14013160A EC SP14013160 A ECSP14013160 A EC SP14013160A
Authority
EC
Ecuador
Prior art keywords
regression
manufacture
pharmaceutical composition
renal failure
chronic renal
Prior art date
Application number
Other languages
English (en)
Inventor
Castro José Agustín Rogelio Magaña
Borunda Juan Socorro Armendariz
Original Assignee
Cell Therapy And Technology S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46940567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013160(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cell Therapy And Technology S A De C V filed Critical Cell Therapy And Technology S A De C V
Publication of ECSP14013160A publication Critical patent/ECSP14013160A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención se relaciona con un procedimiento para la fabricación de una composición farmacéutica en forma de tabletas de liberación prolongada que comprende desde 600 miligramos hasta 2400 miligramos de Pirfenidona (PFD), de manera tal que el fármaco que lo contiene esté biodisponible durante un periodo de tiempo prolongado de 12 horas a partir de su administración. De esta manera se optimiza la acción anti-fibrótica y anti-inflamatoria del medicamento Pirfenidona. Además, la presente invención ofrece ventajas y una mejor eficacia terapéutica sobre otras formas farmacéuticas de Pirfenidona para su administración oral y su aplicación terapéutica en la regresión de la insuficiencia renal crónica secundaria a glomeruloesclerosis primaria; presenta una mejor actividad en la disminución y/o regresión de los efectos nocivos en la contractura capsular mamaria observados después la implantación quirúrgica de implantes mamarios en humanos y ejerce una importante acción anti-TNF- y anti-TGF- 1 para el tratamiento de fibrosis hepática.
ECSP14013160 2011-07-19 2014-01-21 Procedimiento para la fabricación de una composición farmacéutica en forma de tabletas de liberación prolongada conteniendo pirfenidona y su aplicación en la regresión de la insuficiencia renal crónica, contractura capsular mamaria y fibrosis hepatica hu ECSP14013160A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2011007675A MX2011007675A (es) 2011-07-19 2011-07-19 Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.

Publications (1)

Publication Number Publication Date
ECSP14013160A true ECSP14013160A (es) 2014-02-28

Family

ID=46940567

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013160 ECSP14013160A (es) 2011-07-19 2014-01-21 Procedimiento para la fabricación de una composición farmacéutica en forma de tabletas de liberación prolongada conteniendo pirfenidona y su aplicación en la regresión de la insuficiencia renal crónica, contractura capsular mamaria y fibrosis hepatica hu

Country Status (35)

Country Link
US (7) US9408836B2 (es)
EP (2) EP2735306A1 (es)
JP (1) JP6034380B2 (es)
KR (2) KR101632332B1 (es)
CN (2) CN112386579A (es)
AR (1) AR087205A1 (es)
AU (1) AU2012284627B2 (es)
BR (1) BR112014001297B1 (es)
CA (1) CA2842654C (es)
CL (1) CL2014000131A1 (es)
CO (1) CO6970587A2 (es)
CR (1) CR20140019A (es)
CY (2) CY2200005T2 (es)
DE (1) DE15161929T1 (es)
DK (1) DK2907506T3 (es)
DO (1) DOP2014000010A (es)
EC (1) ECSP14013160A (es)
ES (1) ES2550227T3 (es)
HR (1) HRP20180183T1 (es)
HU (1) HUE036511T2 (es)
LT (1) LT2907506T (es)
MX (1) MX2011007675A (es)
NO (1) NO2907506T3 (es)
PE (1) PE20141684A1 (es)
PL (1) PL2907506T3 (es)
PT (1) PT2907506T (es)
PY (1) PY1233418A (es)
RS (1) RS56858B1 (es)
RU (1) RU2682177C2 (es)
SI (1) SI2907506T1 (es)
SM (1) SMT201800081T1 (es)
UA (1) UA114181C2 (es)
UY (1) UY34190A (es)
WO (1) WO2013012307A1 (es)
ZA (1) ZA201400386B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN105050708A (zh) 2012-11-14 2015-11-11 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
CA2937365C (en) * 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CN105997302A (zh) * 2016-07-18 2016-10-12 青岛三帝生物科技有限公司 基于3d打印的防包膜挛缩乳房假体制作方法和乳房假体
MX364040B (es) * 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
KR20180100869A (ko) * 2017-03-02 2018-09-12 영진약품 주식회사 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법
CN107080741A (zh) * 2017-04-28 2017-08-22 北京工业大学 吡非尼酮缓释制剂及制备方法
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
US10980747B2 (en) * 2017-11-27 2021-04-20 Shin-Etsu Chemical Co., Ltd. Composition for solid preparation, solid preparation, and method for producing the same
EP3511001B1 (en) 2018-01-12 2021-09-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Pirfenidone-containing tablet and capsule formulation
CN112004527B (zh) 2018-04-23 2024-09-24 盈擘生技股份有限公司 用于治疗肺部疾病的可吸入脂质体缓释组合物
WO2020115774A1 (en) * 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
KR102199415B1 (ko) * 2019-02-18 2021-01-06 충북대학교 산학협력단 중합체 및 채널링제를 포함하는 피르페니돈 또는 이의 약학적으로 허용가능한 염의 지연 방출용 정제
IL297296A (en) * 2020-04-14 2022-12-01 Excalibur Pharmaceuticals Inc Pirfenidone for the treatment of the corona virus
KR102584268B1 (ko) * 2020-04-22 2023-10-05 영진약품 주식회사 안전성과 안정성이 개선된 피르페니돈을 포함하는 장용성 제제 및 이의 제조방법
CN117815229A (zh) * 2023-12-20 2024-04-05 中国医学科学院整形外科医院 雷帕霉素在包膜增生的产品中的应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES421598A1 (es) 1972-12-18 1977-01-01 Affiliated Med Res Un procedimiento para la sintesis de piridonas.
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US4105782A (en) 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
JPS51128438A (en) 1975-04-26 1976-11-09 Yamanouchi Pharmaceut Co Ltd An antibacterial drug against fish diseases
SE430609B (sv) 1976-12-21 1983-11-28 Sca Development Ab Sett att ur cellulosaderivat framstella absorberande material
US4376118A (en) 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
SU1719047A1 (ru) * 1989-11-09 1992-03-15 Воронежский инженерно-строительный институт Вибрационный гранул тор
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
CA2161648A1 (en) 1993-05-07 1994-11-24 Solomon B. Margolin Compositions and methods for reparation and prevention of fibrotic lesions
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
ATE212551T1 (de) 1995-12-21 2002-02-15 Pfizer Injizierbare quinolonformulierungen
US5958420A (en) 1997-03-13 1999-09-28 Nortrade Medical, Inc. Treatment of burns, cuts, and abrasions of the skin
US6365131B1 (en) 1997-10-31 2002-04-02 J. B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic
JP2002506820A (ja) 1998-03-17 2002-03-05 ビー マーゴリン、ソロモン 局所用防腐組成物および方法
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
US6492395B1 (en) 1998-09-18 2002-12-10 Mepha Ag Topical formulation of alkyl-, phenyl-pyridone
US6277407B1 (en) * 1998-11-10 2001-08-21 Frederick S. Marius Apparatus and method for tablet fabrication
HUP0104606A3 (en) * 1998-12-18 2003-01-28 Basf Ag A pharmaceutical mixture comprising a profen
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
IN191090B (es) 2000-08-29 2003-09-20 Ranbanx Lab Ltd
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
WO2003030720A2 (en) 2001-10-09 2003-04-17 The Children's Hospital Of Philadelphia Materials and methods for preventing or reducing scar formation
CH696420A5 (de) 2002-09-13 2007-06-15 Mepha Ag Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung.
TW200501952A (en) 2003-02-21 2005-01-16 Shionogi & Co Pirfenidone gel formulations
WO2004078194A1 (en) 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2004078207A1 (en) 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2004089283A2 (en) 2003-04-04 2004-10-21 Intermune, Inc. Compositions and methods for treating viral infections
EP1638625A4 (en) 2003-05-23 2009-08-19 David M Ott ORGANOSOUFRES PROMEDICAMENTS FOR PREVENTING AND TREATING INFECTIOUS DISEASES AND A PATHOLOGICAL REACTION OF THE IMMUNE SYSTEM
US20080025986A1 (en) 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
TW201245229A (en) 2003-10-14 2012-11-16 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
WO2005067454A2 (en) 2003-12-23 2005-07-28 Valeant Pharmaceuticals North America Combination therapy for treating hepatitis c virus infection
CN100542532C (zh) 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
US20060051339A1 (en) 2004-09-08 2006-03-09 Sivak Hannah N Composition for treatment of oily skin and acne prevention and methods of making and using same
US20060115503A1 (en) 2004-11-30 2006-06-01 Goyal Muna C Composition, system and method for treatment of skin
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
JP5249028B2 (ja) 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
EP1960405A2 (en) 2005-11-23 2008-08-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
US20070203202A1 (en) * 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
CA2631497C (en) 2005-12-05 2014-04-22 Bioartificial Gel Technologies Inc. Emulsions of a protein-crosslinked hydrogel matrix and dispersed hydrophobic phase
MX2008011952A (es) * 2006-03-21 2008-10-01 Teva Pharma Formulacion de liberacion controlad de tolterodina.
CN101088557A (zh) 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
WO2007147297A1 (fr) * 2006-06-15 2007-12-27 Shanghai Genomics, Inc. Utilisation de dérivés de pyridone destinés à prévenir et traiter par radioactivité une lésion des poumons
JP2010513320A (ja) * 2006-12-18 2010-04-30 インターミューン インコーポレイテッド ピルフェニドン治療を患者に提供する方法
EP2134683A2 (en) 2007-02-12 2009-12-23 Intermune, Inc. Novel inhibitors hepatitis c virus replication
JP2010520194A (ja) 2007-03-02 2010-06-10 ミロン、タリア 抗癌剤としてのメルカプトプリン誘導体
US20080287508A1 (en) 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
MX2007006347A (es) * 2007-05-29 2009-02-18 Cell Therapy And Technology S Nuevo uso de 5-metil-1-fenil-2-(1h)-piridona para el tratamiento y prevencion de cicatrices hipertroficas, y composicion conteniendo la misma.
CA2691379C (en) * 2007-06-20 2015-06-09 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
US20090137354A1 (en) 2007-11-27 2009-05-28 Shimano Inc. Bicycle rear derailleur
CA2709151A1 (en) 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
CN101244045B (zh) * 2007-12-21 2010-06-30 东华大学 一种零级给药口服控释片剂及其制备方法
US20100256031A1 (en) 2008-10-10 2010-10-07 Jeffrey Wu Shine control cleanser
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
TWI434833B (zh) 2009-06-03 2014-04-21 Intermune Inc 用於合成吡非尼酮（ｐｉｒｆｅｎｉｄｏｎｅ）的改良方法
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
CN101972225A (zh) 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的凝胶组合物
ES2913095T3 (es) 2011-01-31 2022-05-31 Avalyn Pharma Inc Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos
KR102058756B1 (ko) 2011-02-15 2020-01-22 어클라리스 쎄라퓨틱스, 인코포레이티드 주사비 징후들의 치료용 옥시메타졸린의 약학 크림 조성물들
CN102670600A (zh) 2011-03-12 2012-09-19 赵海静 一种抑制瘢痕和促进创口愈合的医药产品,其制备方法和应用
CN102670632A (zh) 2011-03-12 2012-09-19 赵海静 吡非尼酮在抑制皮肤瘢痕形成的医药用途
US9241921B2 (en) 2011-05-02 2016-01-26 Pankaj Modi Photosensitizer composition for treating skin disorders
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN102488660A (zh) 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
WO2013181691A1 (en) 2012-06-04 2013-12-12 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor
EA201590006A1 (ru) 2012-06-12 2015-05-29 Ф. Хоффманн-Ля Рош Аг Комбинация терапевтических средств для лечения инфекции, вызванной вирусом гепатита c
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
CN105188758A (zh) 2013-03-15 2015-12-23 梅迪奇斯医药公司 氟尼缩松的局部组合物及治疗方法
MX352342B (es) 2013-07-12 2017-11-22 Moleculas Naturales S A De C V Star Un procedimiento para fabricar un complejo mejorado de cloruro de bencetonio-dialil oxido de disulfuro modificado, el complejo obtenido y sus usos.
CN103550242B (zh) 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
GB201508419D0 (en) 2015-05-15 2015-07-01 Cambridge Entpr Ltd Detection of T cell exhaustion or lack of T cell costimulation and uses thereof
JPWO2017104725A1 (ja) 2015-12-16 2018-10-04 第一三共株式会社 創傷治療剤
JOP20170113B1 (ar) 2016-05-09 2023-03-28 Bayer Pharma AG مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها
MX364040B (es) 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
TWI770157B (zh) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
IL297296A (en) 2020-04-14 2022-12-01 Excalibur Pharmaceuticals Inc Pirfenidone for the treatment of the corona virus

Also Published As

Publication number Publication date
HUE036511T2 (hu) 2018-07-30
US9962374B2 (en) 2018-05-08
DK2907506T1 (en) 2015-10-12
EP2907506A1 (en) 2015-08-19
CN103957892A (zh) 2014-07-30
ES2550227T3 (es) 2018-03-16
HK1208172A1 (en) 2016-02-26
KR20160074016A (ko) 2016-06-27
CA2842654A1 (en) 2013-01-24
CO6970587A2 (es) 2014-06-13
UA114181C2 (uk) 2017-05-10
RS56858B1 (sr) 2018-04-30
AU2012284627A8 (en) 2014-04-10
MX2011007675A (es) 2012-07-11
EP2907506B1 (en) 2017-11-15
WO2013012307A1 (es) 2013-01-24
US20140296300A1 (en) 2014-10-02
PT2907506T (pt) 2018-02-22
CL2014000131A1 (es) 2014-08-22
US20210386724A1 (en) 2021-12-16
EP2735306A1 (en) 2014-05-28
DK2907506T3 (en) 2018-02-19
US20180092893A1 (en) 2018-04-05
US20190358213A1 (en) 2019-11-28
HUE15161929T1 (hu) 2016-06-28
HRP20180183T1 (hr) 2018-03-09
CY2200005T2 (el) 2016-04-13
US20160287567A1 (en) 2016-10-06
LT2907506T (lt) 2018-03-12
SI2907506T1 (en) 2018-03-30
RU2014101231A (ru) 2015-08-27
KR101632332B1 (ko) 2016-06-22
ES2550227T1 (es) 2015-11-05
KR20140057248A (ko) 2014-05-12
BR112014001297A2 (pt) 2017-02-21
US12083106B2 (en) 2024-09-10
CA2842654C (en) 2020-09-15
NO2907506T3 (es) 2018-04-14
CN112386579A (zh) 2021-02-23
US20250213539A1 (en) 2025-07-03
RU2682177C2 (ru) 2019-03-15
AU2012284627A1 (en) 2014-02-27
US9408836B2 (en) 2016-08-09
PY1233418A (es) 2017-09-01
BR112014001297B1 (pt) 2021-11-16
UY34190A (es) 2013-02-28
AU2012284627B2 (en) 2017-07-20
CR20140019A (es) 2014-05-20
US11040030B2 (en) 2021-06-22
JP2014522861A (ja) 2014-09-08
SMT201800081T1 (it) 2018-03-08
AR087205A1 (es) 2014-02-26
DE15161929T1 (de) 2015-11-12
US10383862B2 (en) 2019-08-20
PL2907506T3 (pl) 2018-07-31
US20200038386A1 (en) 2020-02-06
JP6034380B2 (ja) 2016-11-30
DOP2014000010A (es) 2014-06-30
ZA201400386B (en) 2015-04-29
CY1119886T1 (el) 2018-06-27
US11052074B2 (en) 2021-07-06
PE20141684A1 (es) 2014-11-13

Similar Documents

Publication Publication Date Title
DOP2014000010A (es) Procedimiento para la fabricación de una composición farmacéutica en forma de tabletas de liberación prolongada conteniendo pirfenidona y su aplicación en la regresion de la insuficiencia renal crónica, contractura capsular mamaria y fibrosis hepatica humanas.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
JP2015038135A5 (es)
AR094374A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
NZ715686A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
EA201270617A2 (ru) Способы лечения или предотвращения тромбоза стента
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
AR072795A1 (es) Una formulacion de fenofibrato, una capsula para administracion oral que comprende dicha formulacion y un proceso para la fabricacion de dicha formulacion
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite
UY33468A (es) Agente terapeutico de liberacion sostenida para la hipertension y la disfunción renal
NZ740627A (en) Oral suspension for treating eosinophilic esophagitis
CY1120669T1 (el) Συνδυαστικη θεραπεια για αγωγη σκληρυνσης κατα πλακας
RU2014125701A (ru) Фармацевтическая композиция для профилактики или лечения гипертриглицеридемии или вызванных гипертриглицеридемией заболеваний
AR098924A1 (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida
UY31212A1 (es) Composición farmacéutica que comprende la combinación de un agente derivado benzisoxazolico y un agente benzodiazepinico
CU20180036A7 (es) Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana
TH147179A (th) กระบวนการสำหรับการเตรียมขององค์ประกอบทางเภสัชกรรมที่บรรจุเพียร์เฟนิโดนในรูปยาเม็ดชนิดปลดปล่อยเนิ่นนาน และการใช้ของสิ่งนั้นในการทุเลาของ ภาวะไตวายเรื้อรัง, ภาวะพังผืดหดรัดของเต้านม, และ ภาวะพังผืดที่ตับของมุนษย์
AR060531A1 (es) Formulaciones de dosificacion oral de polipeptidos resistentes a proteasas y usos de los mismos para tratamiento